OGN News and Press, Organon & Co. From 12/12/22

DARE -PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include : Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST. Inv...

Organon ( NYSE: OGN ) said Ontruzant, a biosimilar of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) cancer drug Herceptin, to treat Canadian adults with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) was now availa...

Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost Canada NewsWire KIRKLAND, QC , Nov. 14,...

Organon ( NYSE: OGN ) had declared $0.28/share quarterly dividend , in line with previous. Payable Dec. 15; for shareholders of record Nov. 14; ex-div Nov. 10. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organo...

Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer Canada NewsWire KIRKLAND, QC , Nov. 7, 2022 /CNW/ - Organon...

The following slide deck was published by Organon & Co. in conjunction with their 2022 Q3 earnings call. For further details see: Organon & Co. 2022 Q3 - Results - Earnings Call Presentation

Organon & Co. (OGN) Q3 2022 Earnings Conference Call November 03, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Sand...

Merck ( MRK ) spinoff Organon & Co. ( NYSE: OGN ) rose after its Q3 2021 financials topped Street forecasts on Thursday, even as the company reported a decline in revenue for the second consecutive quarter. Revenue for the quarter fell ~4% YoY on a GAAP basis to ...

Organon press release ( NYSE: OGN ): Q3 Non-GAAP EPS of $1.32 beats by $0.22 . Revenue of $1.54B (-3.8% Y/Y) beats by $20M . Full year 2022 financial guidance ranges updated: Revenue range narrowed to $6.1 billion to $6.2 billion and reflects persisting for...